National Health Act 1953 - Declaration under subsection 85(2AA) (30/03/1988)

Overview

The National Health Act 1953 was enacted by the Australian Parliament to establish a framework for the provision of health services, including the regulation of drugs and medicinal preparations through the Pharmaceutical Benefits Scheme. This legislation aimed to fill a significant gap by providing a coordinated approach to the supply and subsidy of medicines, ensuring that essential drugs were accessible and affordable to the public. The Act was designed to facilitate the provision of healthcare services by regulating the pharmaceutical sector and establishing a national scheme for the provision of benefits in respect of medical services, hospital services, and pharmaceuticals. The policy objective was to enhance the health and wellbeing of Australians by making necessary medications more readily available and affordable. The legislative instrument F2007B00990, which is a declaration under sub-section 85(2AA) of the National Health Act 1953, was introduced to update the list of drugs and medicinal preparations that are subject to the provisions of the Act. This particular declaration, made by John Stewart Deeble, Acting First Assistant Secretary of the Health Benefits Division, specifies certain drugs and preparations that would cease to be subject to Part VII of the Act, effective from 1 April 1988.

Scope and Application

The Declaration under sub-section 85(2AA) of the National Health Act 1953, made by John Stewart Deeble, Acting First Assistant Secretary of the Health Benefits Division in the Department of Community Services and Health, specifically addresses the applicability of Part VII of the Act to certain drugs and medicinal preparations. This Act, which operates at the Commonwealth level, affects pharmaceutical entities and individuals involved in the provision or distribution of these medications. The Declaration delineates the cessation of the application of Part VII to the listed drugs and medicinal preparations, effective from 1 April 1988. These substances, detailed in the Schedule, no longer fall under the provisions of the National Health Act as pertains to their regulation and benefits. The jurisdictional reach of this legislative instrument is national, applying uniformly across Australia. The exclusion of these particular pharmaceutical products from the Act’s purview is explicitly stated and is effective from the date of the Declaration, without any further need for subordinate instruments to extend or restrict its application.

Key Provisions

The primary operative sections of this Declaration under sub-section 85(2AA) of the National Health Act 1953, specify that certain drugs and medicinal preparations listed in the Schedule will cease to be subject to Part VII of the Act, which pertains to the Pharmaceutical Benefits Scheme. Specifically, Section 85(2AA) provides the authority for the Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health, as the Delegate of the Minister, to issue such a Declaration. This effective change removes the listed drugs and preparations from the scope of the Pharmaceutical Benefits Scheme, thereby altering their eligibility for government subsidies or coverage under the Act. The Declaration is set to come into operation on 1 April 1953, as stated in the document. This Act imposes specific obligations on the parties it governs, particularly those involved in the pharmaceutical sector and the Health Benefits Division. The obligation falls on the Acting First Assistant Secretary, as the Delegate of the Minister, to ensure that the listed drugs and preparations are administratively and legally removed from the Pharmaceutical Benefits Scheme. This involves updating relevant databases, informing stakeholders, and ensuring compliance with the changes outlined in the Declaration. The pharmaceutical companies and healthcare providers must also adjust their billing and reimbursement practices to reflect these changes, ensuring that they no longer claim subsidies for the specified drugs and preparations under the Pharmaceutical Benefits Scheme. Breach of the provisions outlined in this Declaration could result in various civil and criminal consequences. For instance, if pharmaceutical companies or healthcare providers continue to claim subsidies for the drugs and preparations listed in the Schedule after the effective date, they may be subject to penalties under the National Health Act 1953. The specific penalties are not detailed in the text provided but generally, penalties for such breaches can include fines, reimbursement of claimed benefits, and potential legal action. The maximum penalties could vary based on the nature and extent of the breach, but they are typically significant enough to deter non-compliance. It is essential for all parties governed by the Act to adhere to the changes specified in the Declaration to avoid these consequences.